The current achievements in treating glioblastoma (GBM) patients are not sufficient because
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem …

Among central nervous system tumors, Glioblastoma (GBM) is the most common, aggressive
and neurological destructive primary brain tumor in adults. Standard care therapy for GBM …

Glioblastoma (GBM) is a particularly aggressive brain cancer associated with high
recurrence and poor prognosis. The standard of care, surgical resection followed by …

Glioblastoma (GBM) is an aggressive malignancy of the central nervous system (CNS) that
remains incurable despite the multitude of improvements in cancer therapeutics. The …

The unique interfacial properties, huge diversity, and biocompatible nature of phospholipids
make them an attractive pharmaceutical excipient. The amphiphilic nature of these …

Glioblastoma (GBM) is the most common malignant adult brain cancer with no curative
treatment strategy. A significant hurdle in GBM treatment is effective therapeutic delivery to …

The local delivery of chemotherapeutic agents is a very promising strategy for the treatment
of glioblastoma (GBM). Gemcitabine is a chemotherapeutic agent that has a different …

Many drug molecules that are currently in the market suffer from short half-life, poor
absorption, low specificity, rapid degradation, and resistance development. The design and …

Glioblastoma is the most aggressive form of brain tumor, accounting for the highest mortality
and morbidity rates. Current treatment for patients with glioblastoma includes maximal safe …

Background Glioblastoma, or glioblastoma multiforme (GBM), remains a fatal cancer type
despite the remarkable progress in understanding the genesis and propagation of the tumor …